-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, JdFwayM1yGzKBiY3l1xmTU1aoU2sAA5NKJWAoduZ0ZoQvRrBnzqZ0YUHDQL7aiTY o96o8Zvs5OM72mOVLu+Odg== 0001209191-05-004402.txt : 20050124 0001209191-05-004402.hdr.sgml : 20050124 20050124154920 ACCESSION NUMBER: 0001209191-05-004402 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20050114 FILED AS OF DATE: 20050124 DATE AS OF CHANGE: 20050124 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: LUNDEMOSE ANKER MD, PH.D, DSC CENTRAL INDEX KEY: 0001314821 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 000-15190 FILM NUMBER: 05544435 BUSINESS ADDRESS: BUSINESS PHONE: 631-962-2000 MAIL ADDRESS: STREET 1: C/O OSI PHARMACEUTICALS, INC. STREET 2: 58 SOUTH SERVICE ROAD, SUITE 110 CITY: MELVILLE STATE: NY ZIP: 11747 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: OSI PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000729922 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 133159796 STATE OF INCORPORATION: DE FISCAL YEAR END: 1204 BUSINESS ADDRESS: STREET 1: 58 SOUTH SERVICE RD. STREET 2: SUITE 110 CITY: MELVILLE STATE: NY ZIP: 11747 BUSINESS PHONE: 631-962-2000 MAIL ADDRESS: STREET 1: 58 SOUTH SERVICE RD. STREET 2: SUITE 110 CITY: MELVILLE STATE: NY ZIP: 11747 FORMER COMPANY: FORMER CONFORMED NAME: ONCOGENE SCIENCE INC DATE OF NAME CHANGE: 19920703 3 1 doc3.xml FORM 3 SUBMISSION X0202 3 2005-01-14 0 0000729922 OSI PHARMACEUTICALS INC OSIP 0001314821 LUNDEMOSE ANKER MD, PH.D, DSC C/O OSI PHARMACEUTICALS, INC. 58 SOUTH SERVICE ROAD, SUITE 110 MELVILLE NY 11747 0 0 0 1 See remarks Stock Option (Right to Buy) 35.10 2005-02-11 2014-02-10 Common Stock 15200 D One third of the stock option will become exercisable one year after the date of the grant and the remainder will vest ratably on a monthly basis over the succeeding 24 months. Includes only options with the same termination date. Dr. Lundemose is Chief Executive Officer of Prosidion, Ltd., a majority-owned subsidiary of OSI Pharmaceuticals, Inc. Anker Lundemose 2005-01-18 EX-24.3_69716 2 poa.txt POA DOCUMENT LIMITED POWER OF ATTORNEY FOR SECTION 16 REPORTING OBLIGATIONS KNOW ALL MEN BY THESE PRESENTS, that the undersigned hereby constitutes and appoints Robert L. Van Nostrand the undersigned's true and lawful attorney-in-fact and agent, with full power of substitution and re-substitution, for the undersigned and in the undersigned's name, place and stead, to execute and file with the appropriate offices on the undersigned's behalf all Forms 3, 4 and 5 under Section 16 of the Securities Exchange Act of 1934, as amened, with respect to the undersigned's transactions in, and ownership of, the securities of OSI Pharmaceuticals, Inc., a Deleware corporation, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act deemed requisite and necessary to be done in order to carry out the foregoing as fully and to all intents and purposes as the undersigned might and could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent or his substitute or substitutes may lawfully do or cause to be done by virtue hereof. IN WITNESS WHEREOF, the undersigned has executed this Power of Attorney as of the 18th day of January, 2005. Anker Lundemose,M.D.,Ph.D,DSC Signature Anker Lundemose,M.D.,Ph.D,DSC Print Name STATE OF NEW YORK COUNTY OF SUFFOLK On this 18th day of January, 2005, Anker Lundemose personally appeared before me, and acknowledged that s/he executed the foregoing instrument for the purposes therein contained. IN WITNESS WHEREOF, I have hereunto set my hand and official seal. Deborah A. Rocklein Notary Public September 8, 2006 My Commission Expires: -----END PRIVACY-ENHANCED MESSAGE-----